Compare Organon Pharma Indonesia Tbk. (SCPI) vs Sinergi Multi Lestarindo Tbk. (SMLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Sinergi Multi Lestarindo Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Sinergi Multi Lestarindo Tbk. trades at Rp185 (market cap 444.68B, 19.41M 24h volume). The key difference: Sinergi Multi Lestarindo Tbk. is far larger — about 4.3× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | SMLE | |
|---|---|---|
Market Cap | 104.4B | 444.68B |
Volume | — | 19.41M |
Lot | — | 194.13K |
Turnover | — | 3.66B |
Average Price | — | 188.72 |
Value | — | 3.66B |
Indicative Equilibrium Price | — | 185 |
Indicative Equilibrium Volume | — | 388 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →About Sinergi Multi Lestarindo Tbk.
PT Sinergi Multi Lestarindo Tbk (the Company) was established based on Deed No. 5 dated March 18, 2013 by Aryadi, S.H., M.Kn., Notary in Tangerang. PT Sinergi Asia Corporindo is the parent entity of the Company and Siu Min is the ultimate beneficiary owner of the Company.
Read more on SMLE →
